This includes the use of inhibitors of the nuclear receptors ER, AR and GR (Glucocorticoid receptor) for the treatment of breast, prostate and lymphoid cancers, respectively, and the use of all trans retinoic acid for treating acute promyelocytic leukemia patients harboring PML-RARα gene fusions [116]. The gene discussed is NR3C1; the disease is acute promyelocytic leukemia.